The management of painful bone metastases with an emphasis on radionuclide therapy

Darren J. Hillegonds, Stephen Franklin, David K. Shelton, Srinivasan Vijayakumar, Vani Vijayakumar

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: This review provides an update on the management of painful bone metastases, with an emphasis on radionuclide therapy, and introduces oligometastases and quantitative imaging evaluations for clinical trials. Methods: The current use of radionuclides, alone and in combination with chemotherapy and radiation therapy for painful bone metastases, is discussed, including toxicity, cost and overall outcomes. Results: Radionuclide therapy is shown to be a useful and cost-effective means of alleviating bone pain in metastatic disease and may be more effective when combined with chemotherapy, bisphosphonates and radiation therapy. Early use of radionuclides in pain therapy may limit cancer progression by inhibiting oligometastases development. Thus, radionuclides can significantly decrease patient morbidity, prolong patient survival, and may decrease the occurrence of new bone metastases. Conclusion: Palliative pain therapy is critical for effectively managing bone metastases, with treatment options including analgesics, external beam radiotherapy, chemotherapy and radionuclides. Radionuclide therapy is underutilized. Recent studies using radionuclides with chemotherapy and bisphosponates, or using newer radionuclides or combinations of radionuclides and treatment paradigms (e.g., higher activities, repetitive or cyclic administration, chemo sensitization, chemo supplementation), are encouraging. A comprehensive, inter-disciplinary clinical approach is needed. Clinical collaborations will optimize radionuclide therapy for pain palliation and increase awareness of its benefits.

Original languageEnglish (US)
Pages (from-to)785-794
Number of pages10
JournalJournal of the National Medical Association
Volume99
Issue number7
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Radioisotopes
Neoplasm Metastasis
Bone and Bones
Therapeutics
Pain
Radiotherapy
Drug Therapy
Costs and Cost Analysis
Diphosphonates
Combination Drug Therapy
Palliative Care
Analgesics
Clinical Trials
Morbidity
Survival

Keywords

  • Bone
  • Cancer
  • Metastasis
  • Pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hillegonds, D. J., Franklin, S., Shelton, D. K., Vijayakumar, S., & Vijayakumar, V. (2007). The management of painful bone metastases with an emphasis on radionuclide therapy. Journal of the National Medical Association, 99(7), 785-794.

The management of painful bone metastases with an emphasis on radionuclide therapy. / Hillegonds, Darren J.; Franklin, Stephen; Shelton, David K.; Vijayakumar, Srinivasan; Vijayakumar, Vani.

In: Journal of the National Medical Association, Vol. 99, No. 7, 07.2007, p. 785-794.

Research output: Contribution to journalArticle

Hillegonds, DJ, Franklin, S, Shelton, DK, Vijayakumar, S & Vijayakumar, V 2007, 'The management of painful bone metastases with an emphasis on radionuclide therapy', Journal of the National Medical Association, vol. 99, no. 7, pp. 785-794.
Hillegonds DJ, Franklin S, Shelton DK, Vijayakumar S, Vijayakumar V. The management of painful bone metastases with an emphasis on radionuclide therapy. Journal of the National Medical Association. 2007 Jul;99(7):785-794.
Hillegonds, Darren J. ; Franklin, Stephen ; Shelton, David K. ; Vijayakumar, Srinivasan ; Vijayakumar, Vani. / The management of painful bone metastases with an emphasis on radionuclide therapy. In: Journal of the National Medical Association. 2007 ; Vol. 99, No. 7. pp. 785-794.
@article{a3d80ab30d9643a8b847faa53e1e89a5,
title = "The management of painful bone metastases with an emphasis on radionuclide therapy",
abstract = "Objective: This review provides an update on the management of painful bone metastases, with an emphasis on radionuclide therapy, and introduces oligometastases and quantitative imaging evaluations for clinical trials. Methods: The current use of radionuclides, alone and in combination with chemotherapy and radiation therapy for painful bone metastases, is discussed, including toxicity, cost and overall outcomes. Results: Radionuclide therapy is shown to be a useful and cost-effective means of alleviating bone pain in metastatic disease and may be more effective when combined with chemotherapy, bisphosphonates and radiation therapy. Early use of radionuclides in pain therapy may limit cancer progression by inhibiting oligometastases development. Thus, radionuclides can significantly decrease patient morbidity, prolong patient survival, and may decrease the occurrence of new bone metastases. Conclusion: Palliative pain therapy is critical for effectively managing bone metastases, with treatment options including analgesics, external beam radiotherapy, chemotherapy and radionuclides. Radionuclide therapy is underutilized. Recent studies using radionuclides with chemotherapy and bisphosponates, or using newer radionuclides or combinations of radionuclides and treatment paradigms (e.g., higher activities, repetitive or cyclic administration, chemo sensitization, chemo supplementation), are encouraging. A comprehensive, inter-disciplinary clinical approach is needed. Clinical collaborations will optimize radionuclide therapy for pain palliation and increase awareness of its benefits.",
keywords = "Bone, Cancer, Metastasis, Pain",
author = "Hillegonds, {Darren J.} and Stephen Franklin and Shelton, {David K.} and Srinivasan Vijayakumar and Vani Vijayakumar",
year = "2007",
month = "7",
language = "English (US)",
volume = "99",
pages = "785--794",
journal = "Journal of the National Medical Association",
issn = "1943-4693",
publisher = "National Medical Association",
number = "7",

}

TY - JOUR

T1 - The management of painful bone metastases with an emphasis on radionuclide therapy

AU - Hillegonds, Darren J.

AU - Franklin, Stephen

AU - Shelton, David K.

AU - Vijayakumar, Srinivasan

AU - Vijayakumar, Vani

PY - 2007/7

Y1 - 2007/7

N2 - Objective: This review provides an update on the management of painful bone metastases, with an emphasis on radionuclide therapy, and introduces oligometastases and quantitative imaging evaluations for clinical trials. Methods: The current use of radionuclides, alone and in combination with chemotherapy and radiation therapy for painful bone metastases, is discussed, including toxicity, cost and overall outcomes. Results: Radionuclide therapy is shown to be a useful and cost-effective means of alleviating bone pain in metastatic disease and may be more effective when combined with chemotherapy, bisphosphonates and radiation therapy. Early use of radionuclides in pain therapy may limit cancer progression by inhibiting oligometastases development. Thus, radionuclides can significantly decrease patient morbidity, prolong patient survival, and may decrease the occurrence of new bone metastases. Conclusion: Palliative pain therapy is critical for effectively managing bone metastases, with treatment options including analgesics, external beam radiotherapy, chemotherapy and radionuclides. Radionuclide therapy is underutilized. Recent studies using radionuclides with chemotherapy and bisphosponates, or using newer radionuclides or combinations of radionuclides and treatment paradigms (e.g., higher activities, repetitive or cyclic administration, chemo sensitization, chemo supplementation), are encouraging. A comprehensive, inter-disciplinary clinical approach is needed. Clinical collaborations will optimize radionuclide therapy for pain palliation and increase awareness of its benefits.

AB - Objective: This review provides an update on the management of painful bone metastases, with an emphasis on radionuclide therapy, and introduces oligometastases and quantitative imaging evaluations for clinical trials. Methods: The current use of radionuclides, alone and in combination with chemotherapy and radiation therapy for painful bone metastases, is discussed, including toxicity, cost and overall outcomes. Results: Radionuclide therapy is shown to be a useful and cost-effective means of alleviating bone pain in metastatic disease and may be more effective when combined with chemotherapy, bisphosphonates and radiation therapy. Early use of radionuclides in pain therapy may limit cancer progression by inhibiting oligometastases development. Thus, radionuclides can significantly decrease patient morbidity, prolong patient survival, and may decrease the occurrence of new bone metastases. Conclusion: Palliative pain therapy is critical for effectively managing bone metastases, with treatment options including analgesics, external beam radiotherapy, chemotherapy and radionuclides. Radionuclide therapy is underutilized. Recent studies using radionuclides with chemotherapy and bisphosponates, or using newer radionuclides or combinations of radionuclides and treatment paradigms (e.g., higher activities, repetitive or cyclic administration, chemo sensitization, chemo supplementation), are encouraging. A comprehensive, inter-disciplinary clinical approach is needed. Clinical collaborations will optimize radionuclide therapy for pain palliation and increase awareness of its benefits.

KW - Bone

KW - Cancer

KW - Metastasis

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=34447526656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447526656&partnerID=8YFLogxK

M3 - Article

VL - 99

SP - 785

EP - 794

JO - Journal of the National Medical Association

JF - Journal of the National Medical Association

SN - 1943-4693

IS - 7

ER -